Top of the morning to you, and a fine one it is. A shiny sun is hovering over the Pharmalot campus as we approach the middle of the week. After all, this is an accomplishment and a celebratory cup of stimulation is in order to help us move along. And why not? Just consider the alternatives. Meanwhile, another busy day lies ahead. On that note, here are some items of interest. Hope you have a smashing day and keep us in mind if you hear something juicy …
Sanofi is in talks to acquire Actelion Pharmaceuticals while Johnson & Johnson abandoned its own bid for the drug maker, the Wall Street Journal reports. A deal could be valued at as much as $30 billion. Like J&J, Sanofi would be interested in adding Actelion’s rare disease drugs to an aging portfolio of key products that are losing patent protection. Sanofi, you may recall, recently lost a bidding war for Medivation, which Pfizer bought for $14 billion.
An association of people in France who say they were harmed by a Sanofi drug have filed a class action lawsuit against the drug maker, the Associated Press reports. The APESAC says Sanofi has four months to acknowledge that its Depakine anti-convulsant caused birth defects or the case will proceed to a judge. A study found the drug was prescribed to more than 10,000 pregnant women between 2007 and 2014, but Sanofi allegedly didn’t warn about the risks.
About the Author Reprints
